多西紫杉醇联合顺铂及长春瑞滨联合顺铂治疗67例晚期NSCLC 被引量：3

A Comparison of Docetaxel plus Cisplatin and Vinorelbine plus Cisplatin in 67 Cases with Advanced Non-small-cell Lung Cancer

在线阅读下载PDF

导出

摘要 [目的]比较多西紫杉醇联合顺铂(DP)及长春瑞滨联合顺铂(NP)一线治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。[方法]67例经细胞学或病理确诊的NSCLC患者分别接受DP(34例)或NP方案(33例)化疗,观察两组缓解率(RR)、疾病进展时间(TTP)、中位生存时间(MST)和1年、2年生存率。[结果]DP组CR1例、PR14例、RR44.1%、TTP6.5个月、MST10.6个月,1年生存率47.1%,2年生存率23.5%。NP组无CR、PR10例、RR30.3%、TTP4.7个月、MST8.5个月。1年生存率33.3%,2年生存率12.1%。两组肿瘤缓解率差异有统计学意义(P=0.046)。不良反应两组相似,无统计学意义。[结论]多西紫杉醇联合顺铂方案一线治疗晚期非小细胞肺癌,肿瘤缓解率优于长春瑞滨联合顺铂,有较好的耐受性及较高的临床缓解率;但1年及2年生存率差异无显著性。

作者王蓉王宇岭王庆才

机构地区苏州大学附属第一医院

出处《中国肿瘤》 CAS 2007年第6期476-477,共2页 China Cancer

关键词癌非小细胞肺药物疗法多西紫杉醇长春瑞滨顺铂

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献5

1Gridelli C,Ardizzoni A,Le Chevalier T,et al.Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2:results of an European Experts Panel[J].Ann Oncol,2004,15(3):419-426.
2Shepherd FA,Dancey,Ramlau R,et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy[J].J Clin Oncol,2000,18(10):2095 -2103.
3吴荻,赵大伟,景年才,张延铭.长春瑞滨联合顺铂治疗晚期非小细胞肺癌56例临床研究[J].实用肿瘤学杂志,2005,19(2):139-140. 被引量：9
4Furuse K,Kubota K,Kawahara M,et al.A phase Ⅱ study of vinordlbine,a new derivative of vinca alkaloid,for previously untreated advanced non-small cell lung cancer.Jopan Vinorelbine Lung Cancer Study Group[J].Lung Cancer,1994,11(5-6):385-391.
5Stephens RJ,Fairlamb D,Gower N,et al.The big lung trail (BLT):determining the value of cisplatine based chemotherapy for patients with non-small cacncer(NSCLC).Preliminary results in the supportive care setting[C].USA Proc ASCO,2002.

二级参考文献3

1Vallejo C, Romoero A, Perez J, et al. Ifosfamide and vinorelbine as first- line chemotherapy for advance non - small cell lung cancer [J].Am J Clin Oncol, 1996;19(6):584.
2张载福.炎症介质[A].见:王迪浔主编.病理生理学[C].北京:人民卫生出版社,1996.109-112.
3蔡菊芬,徐农,钟海均,张沂平,范云,余新民,孙琳.以去甲长春花碱为主联合化疗治疗晚期非小细胞肺癌近期疗效观察[J].中国肿瘤临床,1999,26(9):681-684. 被引量：15

共引文献8

1周超,胡斌,彭卫东,方平.NP方案与TP方案对初治晚期非小细胞肺癌疗效的对比观察[J].临床肿瘤学杂志,2006,11(10):749-751. 被引量：10
2马波,尹德刚.肺癌化疗新进展[J].临床肺科杂志,2007,12(10):1102-1103. 被引量：1
3王保庆.TP方案治疗NP方案化疗失败的非小细胞肺癌的疗效观察[J].肿瘤基础与临床,2007,20(6):497-498.
4李京华,郭云岭,高凌峰,崔慧娟,李园,谭煌瑛.TP与NP方案治疗晚期非小细胞肺癌的临床观察[J].中华肿瘤防治杂志,2009,16(1):55-57. 被引量：11
5欧传活,吴建语,刘有滕,文军程.NP方案与TP方案治疗晚期非小细胞肺癌48例疗效观察[J].广西医学,2009,31(5):659-661. 被引量：7
6任玲,夏媛,操乐杰.长春瑞滨联用顺铂与吉西他滨联用顺铂治疗晚期非小细胞肺癌的临床观察[J].中国临床保健杂志,2010,13(2):124-126. 被引量：11
7张莹,张建柱,王正帅,杨定忠.亲水作用色谱法测定长春瑞滨的含量[J].广州化工,2010,38(7):159-160. 被引量：1
8徐利兵.NP与TP方案治疗晚期非小细胞肺癌的临床疗效分析[J].肿瘤基础与临床,2012,25(2):125-127. 被引量：3

同被引文献31

1陈颖波,陈嘉,陈凌翔,蔡炜宇,黄富麟.多西他赛联合顺铂三周方案与每周方案治疗非小细胞肺癌[J].中国癌症杂志,2005,15(2):169-170. 被引量：25
2段家华,王志刚.国产多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中华肿瘤防治杂志,2006,13(17):1333-1335. 被引量：23
3王振兴.非小细胞肺癌的治疗[J].医学综述,2007,13(9):690-692. 被引量：5
4Kim YH, Kim JS, Choi YH, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non - small cell lung cancer[ J]. Int J Clin Oncot,2002,7(2) :114 -119.
5Comer AM , Goa KL. Docetaxel : a review of its use in non - small- cell lung cancer[ J]. Drugs Aging ,2000,17 ( 1 ) :53 - 80.
6Belani CP. Optimizing chemotherapy for advanced non - small cell- lung cancer : focus on docetaxel [ J ]. Lung Cancer, 2005, 50 ( Suppl2 ) : S3 - S8.
7Schuette W,Nagel S,Blankenburg T,et al. Phase Ⅲ study of second - line chemotherapy for advanced non - small cell lung cancer with weekly compared with 3 - weekly docetaxel [ J ]. J Clin Oncol,2005,23 ( 33 ) :8389 - 8395.
8Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non - small - cell lung cancer: Meta - analysis of randomized trials [ J]. Cancer Treat Rev, 2006,32(8) :583 -587.
9Belani CP. Optimizing chemotherapy for advanced non-small-cell lung cancer: focus on docetaxel [ J ]. Lung Cancer, 2005,50 ( Suppl2 ) : S3- S8.
10FosseUa F, Pereira JR, yon Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versusvinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group[ J]. J Clin Oncol,2003,21 (16) :3016-3024.